Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether she plans to expand the availability of Evusheld as a prophylactic through clinical trials.

Following engagement with AstraZeneca, we have encouraged the company to continue discussions with the Antivirals and Therapeutics Taskforce (ATTF) and the Chief Scientific Adviser on options for evaluating the clinical effectiveness of Evusheld. Clinical advisers have recommended a United Kingdom clinical trial to generate sufficient data to understand Evusheld’s effectiveness against current and future variants. The ATTF are currently considering options for such a trial.